换一批MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition.
第一作者：
Matthew J,Fell
第一单位：
Neuroscience Discovery (M.J.F., C.M., M.E.K) and Discovery Chemistry (J.M.E), Merck Research Laboratories, Boston, Massachusetts; Discovery Chemistry (K.B., D.E.D., M.M., J.D.S.), Pharmacology (B.C., L.A.H., Y.L., E.M.P., M.D.S., Z.Y., X.Z.), Pathology and Cellular Toxicology (C.G.M., F.M.P), and Pharmacokinetics (H.M.), Merck Research Laboratories, Kenilworth, New Jersey; Neuroscience Discovery, Merck Research Laboratories, West Point, Pennsylvania (J.A.M.) matthew.fell@merck.com.
作者：
医学主题词
动物(Animals);抗震颤麻痹药(Antiparkinson Agents);行为, 动物(Behavior, Animal);结合, 竞争性(Binding, Competitive);脑(Brain);脑化学(Brain Chemistry);细胞系(Cell Line);大脑皮质(Cerebral Cortex);剂量效应关系, 药物(Dose-Response Relationship, Drug);人类(Humans);吲唑类(Indazoles);肺(Lung);男(雄)性(Male);小鼠(Mice);小鼠, 近交C57BL(Mice, Inbred C57BL);突变(Mutation);帕金森病(Parkinson Disease);磷酰化(Phosphorylation);蛋白激酶抑制剂(Protein Kinase Inhibitors);嘧啶类(Pyrimidines)
DOI
10.1124/jpet.115.227587
PMID
26407721
发布时间
2025-03-06
- 浏览30
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
